HIV update 2005: Origins, issues, prospects, and complications.
Wendy Armstrong, MD
Department of Infectious Disease, The Cleveland Clinic Foundation
Leonard Calabrese, DO
Department of Rheumatic and Immunologic Disease, The Cleveland Clinic Foundation
Alan J. Taege, MD
Department of Infectious Disease, The Cleveland Clinic
Address: Alan J. Taege, MD, Department of Infectious Disease, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
Dr. Taege has indicated that he serves as a consultant for the Glaxo, BMS, Pfizer, and Merck corporations, is on the speakers’ bureaus of the Glaxo, BMS, and Roche corporations, and is a major stock shareholder in the Amgen corporation.
Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.
ABSTRACTMorbidity and mortality rates of human immunodeficiency virus (HIV) have plummeted where highly active antiretroviral therapy (HAART) is available. However, therapy is out of reach for most people who need it in developing nations, where the infrastructure to deliver care and resources for medications is lacking. Worldwide, the epidemic is increasing at alarming rates.